Neutral
Lunai Bioworks (NASDAQ: LNAI) issues $20M preferred to acquire CNS patents, aid Nasdaq equity test
Lunai Bioworks acquired Neurobridge IP Holdings, a company whose sole assets are a multi-jurisdictional patent portfolio for Alzheimer’s disease and n...